| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8953241 | European Urology Oncology | 2018 | 9 Pages |
Abstract
Checkpoint inhibitor (CPI) therapy has provided durable tumor control in a small portion of patients with metastatic urothelial carcinoma (UC). Investigating the potential for similar sustained tumor control in localized UC is logical. Ongoing prospective clinical trials will define whether or not CPI therapy should be extended to patients with curable localized UC in whom standards for successful clinical outcomes are higher and acceptance rates of severe treatment-related toxicity are lower.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Noah M. Hahn, Andrea Necchi, Yohann Loriot, Thomas Powles, Elizabeth R. Plimack, Guru Sonpavde, Morgan Roupret, Ashish M. Kamat,